JP2002522452A - 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン - Google Patents

蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン

Info

Publication number
JP2002522452A
JP2002522452A JP2000563824A JP2000563824A JP2002522452A JP 2002522452 A JP2002522452 A JP 2002522452A JP 2000563824 A JP2000563824 A JP 2000563824A JP 2000563824 A JP2000563824 A JP 2000563824A JP 2002522452 A JP2002522452 A JP 2002522452A
Authority
JP
Japan
Prior art keywords
dihydroindol
group
hydrogen
indole
methoxybenzylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000563824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002522452A5 (fr
Inventor
タン，ペン，チョー
サン，リー
ミラー，トッド・アンソニー
リャン，コンジン
トラン，エンゴク・マイ
ニュイエン，アン・ティー
ネマタラ，アサード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of JP2002522452A publication Critical patent/JP2002522452A/ja
Publication of JP2002522452A5 publication Critical patent/JP2002522452A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2000563824A 1998-08-04 1999-08-04 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン Withdrawn JP2002522452A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12925698A 1998-08-04 1998-08-04
US09/129,256 1998-08-04
US9547098P 1998-08-05 1998-08-05
US60/095,470 1998-08-05
US10217898P 1998-09-28 1998-09-28
US60/102,178 1998-09-28
US11610799P 1999-01-15 1999-01-15
US60/116,107 1999-01-15
PCT/US1999/017845 WO2000008202A2 (fr) 1998-08-04 1999-08-04 Modulateurs 3-methylidenyl-2-indolinone de proteine kinase

Publications (2)

Publication Number Publication Date
JP2002522452A true JP2002522452A (ja) 2002-07-23
JP2002522452A5 JP2002522452A5 (fr) 2006-09-14

Family

ID=27492796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000563824A Withdrawn JP2002522452A (ja) 1998-08-04 1999-08-04 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン

Country Status (4)

Country Link
JP (1) JP2002522452A (fr)
AU (1) AU5468499A (fr)
CA (1) CA2383623A1 (fr)
WO (1) WO2000008202A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512400A (ja) * 2002-11-27 2006-04-13 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
JP2011037848A (ja) * 2009-08-04 2011-02-24 Lab Servier 新規なジヒドロインドロン化合物、それらの調製方法及びそれらを含む薬学的組成物
JP2012522729A (ja) * 2009-04-06 2012-09-27 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US9139563B2 (en) 2010-04-06 2015-09-22 University Health Network Kinase inhibitors and method of treating cancer
US20160250220A1 (en) 2013-10-18 2016-09-01 University Health Network Treatment for pancreatic cancer
JP2018533600A (ja) * 2015-11-12 2018-11-15 エルジー・ケム・リミテッド ７−アザインドリン−２−オン誘導体又はその薬学的に許容される塩を有効成分として含有する医薬組成物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
KR20010101266A (ko) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 Ｊｎｋ 단백질 키나제의 억제제로서의 4-아릴옥신돌
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
BR9916324A (pt) 1998-12-17 2001-10-02 Hoffmann La Roche 4,5-pirazinoxindóis como inibidores de proteìna quinase
ES2192877T3 (es) * 1998-12-17 2003-10-16 Hoffmann La Roche 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
US20020028828A1 (en) 2000-05-02 2002-03-07 Chung-Chen Wei (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (fr) 2000-06-02 2001-12-13 Sugen, Inc. Derives d'indolinone comme inhibiteurs de phosphatase/proteine kinase
JP2004518669A (ja) 2000-12-20 2004-06-24 スージェン・インコーポレーテッド ４−アリール置換インドリノン
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6797725B2 (en) 2001-04-09 2004-09-28 Sugen, Inc. Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2448076A1 (fr) * 2001-05-24 2002-11-28 Masahiko Hayakawa Derives de 3-quinoleine-2-(1h)-ylideneindoline-2-one
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CA2459879A1 (fr) 2001-09-10 2003-03-20 Sugen, Inc. Derives de 3-(4,5,6,7-tetrahydroindol-2-ylmethylidene)-2-indolinone comme inhibiteurs de kinases
US7015231B2 (en) 2001-09-27 2006-03-21 Smithkline Beecham Corporation Chemical compounds
AU2003284572A1 (en) * 2002-11-22 2004-06-18 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
US7517697B2 (en) * 2003-02-05 2009-04-14 Applied Biosystems, Llc Compositions and methods for preserving RNA in biological samples
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
EP1883403A4 (fr) * 2005-04-29 2011-02-16 Univ Ohio State Res Found Inhibiteurs specifiques contre la tyrosine du recepteur du facteur de croissance des keratinocytes utiles pour prevenir les metastases cancereuses
WO2009030270A1 (fr) * 2007-09-03 2009-03-12 Novartis Ag Dérivés dhydroindoles utilisés pour traiter la maladie de parkinson
EP2235004A4 (fr) 2007-12-21 2011-05-04 Univ Health Network Dérivés d'indolmone à substitution indazolyle, benzimidazolyle, benzotriazolyle en tant qu'inhibiteurs de kinases utilisés dans le traitement du cancer
WO2012048411A1 (fr) * 2010-10-13 2012-04-19 University Health Network Inhibiteurs de plk4 et méthode de traitement du cancer à l'aide de ceux-ci
WO2012142029A2 (fr) * 2011-04-10 2012-10-18 Florida A&M University Modulateurs sélectifs des récepteurs des œstrogènes pour traitement de troubles à médiation par les récepteurs des œstrogènes
JP6116693B2 (ja) 2012-09-13 2017-04-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ障害の処置のための２−オキソ−２，３−ジヒドロ−インドール
US9296730B2 (en) 2012-10-26 2016-03-29 Regents Of The University Of Minnesota Aurora kinase inhibitors
US10487054B2 (en) 2017-04-21 2019-11-26 Regents Of The University Of Minnesota Therapeutic compounds
EP3860976A1 (fr) * 2018-10-05 2021-08-11 Ichnos Sciences S.A. Composés d'indolinone servant d'inhibiteurs de map4k1
WO2022006412A2 (fr) * 2020-07-02 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Conjugués d'inhibiteurs d'ampk et d'agents de dégradation de protac et utilisations associées
GR1010103B (el) * 2020-07-02 2021-10-18 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, 3-ινδολ-2-υλομεθυλιδενο-ινδολιν-2-ονες με δραση αναστολης της αυτοταξινης

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
FR2678911A1 (fr) * 1991-07-10 1993-01-15 Prospection & Inventions Cartouche tubulaire de stockage et d'application d'un produit non solide et ensemble d'entrainement et de poussee pour la cartouche.
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
FR2694004B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512400A (ja) * 2002-11-27 2006-04-13 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
JP2011225582A (ja) * 2002-11-27 2011-11-10 Allergan Inc 疾患の治療のためのキナーゼ阻害剤
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
JP2012522729A (ja) * 2009-04-06 2012-09-27 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US8999968B2 (en) 2009-04-06 2015-04-07 University Health Network Kinase inhibitors and method of treating cancer with same
USRE47731E1 (en) 2009-04-06 2019-11-19 University Health Network Kinase inhibitors and method of treating cancer with same
JP2011037848A (ja) * 2009-08-04 2011-02-24 Lab Servier 新規なジヒドロインドロン化合物、それらの調製方法及びそれらを含む薬学的組成物
JP2013116908A (ja) * 2009-08-04 2013-06-13 Lab Servier 新規なジヒドロインドロン化合物、それらの調製方法及びそれらを含む薬学的組成物
US9907800B2 (en) 2010-04-06 2018-03-06 University Health Network Kinase inhibitors and method of treating cancer
US9579327B2 (en) 2010-04-06 2017-02-28 University Health Network Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones
US9796703B2 (en) 2010-04-06 2017-10-24 University Health Network Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones
US10077255B2 (en) 2010-04-06 2018-09-18 University Health Network Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones
US10358436B2 (en) 2010-04-06 2019-07-23 University Health Network Kinase inhibitors and method of treating cancer
US9139563B2 (en) 2010-04-06 2015-09-22 University Health Network Kinase inhibitors and method of treating cancer
US9642856B2 (en) 2013-10-18 2017-05-09 University Health Network Treatment for pancreatic cancer
US20160250220A1 (en) 2013-10-18 2016-09-01 University Health Network Treatment for pancreatic cancer
JP2018533600A (ja) * 2015-11-12 2018-11-15 エルジー・ケム・リミテッド ７−アザインドリン−２−オン誘導体又はその薬学的に許容される塩を有効成分として含有する医薬組成物

Also Published As

Publication number Publication date
AU5468499A (en) 2000-02-28
WO2000008202A2 (fr) 2000-02-17
WO2000008202A3 (fr) 2000-05-18
WO2000008202A9 (fr) 2000-07-27
CA2383623A1 (fr) 2000-02-17

Similar Documents

Publication Publication Date Title
JP2002522452A (ja) 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
US7119090B2 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1259514B9 (fr) Composes de 3-(pyrolyllactone)-2-indolinone comme inhibiteurs des kinases
JP3663382B2 (ja) ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
WO2000056709A1 (fr) Composes d'indolinone tels que des inhibiteurs de kinase
JP2002511852A (ja) 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
WO2004014368A1 (fr) 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
US6114371A (en) 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
JP2003535847A (ja) 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
JP2002523455A (ja) 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
JP2004502686A (ja) ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
US6689806B1 (en) Indolinone compounds as kinase inhibitors
US6531502B1 (en) 3-Methylidenyl-2-indolinone modulators of protein kinase
US6130238A (en) 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
WO2005016875A2 (fr) 3-cyclopentylidene-1,3-dihydroindol-2-ones geometriquement limitees comme inhibiteurs puissants de proteines kinases
MXPA00011770A (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
CZ20004412A3 (cs) Pyrrolem substituované 2-indoIinony jako inhibitory proteinkinázy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060711

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070205